1
|
Shi Z, Tuomilehto J, Kronfeld-Schor N, Alberti GK, Stern N, El-Osta A, Bilu C, Einat H, Zimmet P. The circadian syndrome predicts cardiovascular disease better than metabolic syndrome in Chinese adults. J Intern Med 2021; 289:851-860. [PMID: 33340184 DOI: 10.1111/joim.13204] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 09/11/2020] [Accepted: 10/19/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND To compare the predictive value of the circadian syndrome (CircS) and Metabolic syndrome (MetS) for cardiovascular disease. METHOD We used the data of 9360 Chinese adults aged ≥40 years from the 2011 China Health and Retirement Longitudinal Study (CHARLS). Of the participants, 8253 people were followed in the 2015 survey. MetS was defined using the harmonized criteria. CircS was based on the components of the International Diabetes Federation (IDF) MetS plus short sleep and depression. The cut-off for CircS was set as ≥4. Multivariable logistic regression analysis was used to examine the associations. RESULTS The prevalence of CircS and MetS was 39.0% and 44.7%. Both MetS and CircS were directly associated with prevalent CVD. The odds ratios for prevalent CVD comparing CircS with MetS, respectively, were 2.83 (95%CI 2.33-3.43) and 2.34 (1.93-2.83) in men, and 2.33 (1.98-2.73) and 1.79 (1.53-2.10) in women. Similar associations were found for incident CVD. The five-year incidence of CVD was 15.1% in CircS and 14.0% in MetS. The number of CircS components has a better predictive power for both prevalent and incident CVD than those of Mets components as indicated by the area under the ROC (AUC). AUC values for CVD in 2011 were higher for CircS than MetS in both men (0.659 (95%CI 0.634-0.684) vs 0.635 (95%CI 0.610-0.661)) and women (0.652 (95%CI 0.632-0.672) vs 0.619 (95%CI 0.599-0.640)). CONCLUSION The circadian syndrome is a strong and better predictor for CVD than the metabolic syndrome in Chinese adults.
Collapse
Affiliation(s)
- Z Shi
- From the, Human Nutrition Department, College of Health Sciences, QU Health, Qatar University, Doha, Qatar
| | - J Tuomilehto
- Department of Public Health, University of Helsinki, Helsinki, Finland
| | | | - G K Alberti
- Department of Endocrinology and Metabolism Imperial, College London, London, UK
| | - N Stern
- Sagol Epigenetics Center, Tel Aviv Medical Center, Tel Aviv, Israel
| | - A El-Osta
- Department of Diabetes, Central Clinical School, Monash University, Melbourne, Vic., Australia.,The Chinese University of Hong Kong, Hong Kong SAR, China
| | - C Bilu
- School of Zoology, Tel Aviv University, Tel Aviv, Israel
| | - H Einat
- School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel Aviv, Israel
| | - P Zimmet
- Sagol Epigenetics Center, Tel Aviv Medical Center, Tel Aviv, Israel.,Department of Diabetes, Central Clinical School, Monash University, Melbourne, Vic., Australia
| |
Collapse
|
2
|
Damri O, Asslih S, Shemesh N, Natour S, Noori O, Daraushe A, Einat H, Kara N, Las G, Agam G. Using mitochondrial respiration inhibitors to design a novel model of bipolar disorder-like phenotype with construct, face and predictive validity. Transl Psychiatry 2021; 11:123. [PMID: 33579900 PMCID: PMC7881114 DOI: 10.1038/s41398-021-01215-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 12/10/2020] [Accepted: 12/14/2020] [Indexed: 12/17/2022] Open
Abstract
We mimicked mild mitochondrial-distress robustly reported in bipolar-disorder (BD) by chronic exposure to uniquely low doses of inhibitors of mitochondrial-respiration complexes in vitro and in vivo. Exposure of the neuronal-originating SH-SY5Y cells to very low dose (10 pM) rotenone, a mitochondrial-respiration complex (Co)I inhibitor, for 72 or 96 h did not affect cell viability and reactive oxygen species (ROS) levels. Yet, it induced a dual effect on mitochondrial-respiration: overshooting statistically significant several-fold increase of most oxygen-consumption-rate (OCR) parameters vs. significantly decreased all OCR parameters, respectively. Chronic low doses of 3-nitropropionic acid (3-NP) (CoII inhibitor) did not induce long-lasting changes in the cells' mitochondria-related parameters. Intraperitoneal administration of 0.75 mg/kg/day rotenone to male mice for 4 or 8 weeks did not affect spontaneous and motor activity, caused behaviors associated with mania and depression following 4 and 8 weeks, respectively, accompanied by relevant changes in mitochondrial basal OCR and in levels of mitochondrial-respiration proteins. Our model is among the very few BD-like animal models exhibiting construct (mild mitochondrial dysfunction), face (decreased/increased immobility time in the forced-swim test, increased/decreased consumption of sweet solution, increased/decreased time spent in the open arms of the elevated plus maze) and predictive (reversal of rotenone-induced behavioral changes by lithium treatment) validity. Our rotenone regime, employing doses that, to the best of our knowledge, have never been used before, differs from those inducing Parkinson's-like models by not affecting ROS-levels and cell-viability in vitro nor motor activity in vivo.
Collapse
Affiliation(s)
- O Damri
- Department of Clinical Biochemistry and Pharmacology and Psychiatry Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev and Mental Health Center, Beer-Sheva, Israel
| | - S Asslih
- Department of Clinical Biochemistry and Pharmacology and Psychiatry Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev and Mental Health Center, Beer-Sheva, Israel
| | - N Shemesh
- Department of Clinical Biochemistry and Pharmacology and Psychiatry Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev and Mental Health Center, Beer-Sheva, Israel
| | - S Natour
- Department of Clinical Biochemistry and Pharmacology and Psychiatry Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev and Mental Health Center, Beer-Sheva, Israel
| | - O Noori
- Department of Clinical Biochemistry and Pharmacology and Psychiatry Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev and Mental Health Center, Beer-Sheva, Israel
| | - A Daraushe
- Department of Clinical Biochemistry and Pharmacology and Psychiatry Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev and Mental Health Center, Beer-Sheva, Israel
| | - H Einat
- School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel Aviv-Yafo, Israel
| | - N Kara
- Department of Clinical Biochemistry and Pharmacology and Psychiatry Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev and Mental Health Center, Beer-Sheva, Israel
- School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel Aviv-Yafo, Israel
| | - G Las
- Department of Clinical Biochemistry and Pharmacology and Psychiatry Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev and Mental Health Center, Beer-Sheva, Israel
| | - G Agam
- Department of Clinical Biochemistry and Pharmacology and Psychiatry Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev and Mental Health Center, Beer-Sheva, Israel.
| |
Collapse
|
3
|
Lugasi L, Grinberg I, Rudnick-Glick S, Okun E, Einat H, Margel S. Designed proteinoid polymers and nanoparticles encapsulating risperidone for enhanced antipsychotic activity. J Nanobiotechnology 2020; 18:149. [PMID: 33087104 PMCID: PMC7580026 DOI: 10.1186/s12951-020-00709-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Accepted: 10/09/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Nanoparticles (NPs) incorporating drug formulations can be used to facilitate passage through biological barriers including the blood-brain barrier (BBB) and increase drug delivery and bioavailability. Hence, NP-based administration may enhance the efficiency of current antipsychotics. Encapsulation within NPs can resolve aqueous solubility problems that not only reduce permeability through the BBB but also affect targeting. The present study describes a new drug delivery system based on proteinoid NPs to explore the possibility of improving drug efficacy. Risperidone (RSP) is a commonly used atypical antipsychotic medication, and was therefore selected for encapsulation by proteinoid NPs. RESULTS Proteinoid polymers with high molecular weight and low polydispersity were synthesized from L-amino acids and poly-L-lactic acid (PLLA) by thermal step-growth polymerization mechanism. RSP-loaded proteinoid NPs were then prepared using a self-assembly process in the presence of RSP, followed by PEGylation. The optimal PEGylated RSP-loaded NPs were characterized in terms of diameter and size distribution, drug loading, ζ-potential, cytotoxicity, biodistribution, and psychopharmacological effects. The findings indicate significantly higher antipsychotic activity of drug-loaded proteinoid NPs compared to free RSP. CONCLUSIONS Proteinoid NPs enhance RSP delivery and may potentially increase drug efficiency by reducing dosage and side effects.
Collapse
Affiliation(s)
- L Lugasi
- Department of Chemistry, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, 5290002, Ramat Gan, Israel
| | - I Grinberg
- Department of Chemistry, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, 5290002, Ramat Gan, Israel
| | - S Rudnick-Glick
- Department of Chemistry, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, 5290002, Ramat Gan, Israel
| | - E Okun
- The Mina and Everard Goodman, Faculty of Life Sciences, Bar-Ilan University, 5290002, Ramat Gan, Israel
| | - H Einat
- The School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, 6818211, Tel Aviv, Israel
| | - S Margel
- Department of Chemistry, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, 5290002, Ramat Gan, Israel.
| |
Collapse
|
4
|
Abstract
The Metabolic Syndrome is a cluster of cardio-metabolic risk factors and comorbidities conveying high risk of both cardiovascular disease and type 2 diabetes. It is responsible for huge socio-economic costs with its resulting morbidity and mortality in most countries. The underlying aetiology of this clustering has been the subject of much debate. More recently, significant interest has focussed on the involvement of the circadian system, a major regulator of almost every aspect of human health and metabolism. The Circadian Syndrome has now been implicated in several chronic diseases including type 2 diabetes and cardiovascular disease. There is now increasing evidence connecting disturbances in circadian rhythm with not only the key components of the Metabolic Syndrome but also its main comorbidities including sleep disturbances, depression, steatohepatitis and cognitive dysfunction. Based on this, we now propose that circadian disruption may be an important underlying aetiological factor for the Metabolic Syndrome and we suggest that it be renamed the 'Circadian Syndrome'. With the increased recognition of the 'Circadian Syndrome', circadian medicine, through the timing of exercise, light exposure, food consumption, dispensing of medications and sleep, is likely to play a much greater role in the maintenance of both individual and population health in the future.
Collapse
Affiliation(s)
- P. Zimmet
- Department of DiabetesCentral Clinical SchoolMonash UniversityMelbourneVic.Australia
- Sagol Center for Epigenetics and MetabolismTel Aviv Medical CenterTel AvivIsrael
| | | | - N. Stern
- Sagol Center for Epigenetics and MetabolismTel Aviv Medical CenterTel AvivIsrael
| | - C. Bilu
- School of ZoologyTel Aviv UniversityTel AvivIsrael
| | - A. El‐Osta
- Department of DiabetesCentral Clinical SchoolMonash UniversityMelbourneVic.Australia
- Department of PathologyThe University of MelbourneParkvilleVic.Australia
- Hong Kong Institute of Diabetes and ObesityPrince of Wales HospitalThe Chinese University of Hong KongHong Kong SARChina
| | - H. Einat
- School of Behavioral SciencesTel Aviv‐Yaffo Academic CollegeTel AvivIsrael
| | | |
Collapse
|
5
|
Kara NZ, Stukalin Y, Einat H. Revisiting the validity of the mouse forced swim test: Systematic review and meta-analysis of the effects of prototypic antidepressants. Neurosci Biobehav Rev 2017; 84:1-11. [PMID: 29128579 DOI: 10.1016/j.neubiorev.2017.11.003] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2017] [Revised: 11/01/2017] [Accepted: 11/01/2017] [Indexed: 01/03/2023]
Abstract
One problem area regarding animal models for affective disorders is unclear reproducibility, including external validity or generalizability. One way to evaluate external validity is with systematic reviews and meta-analyses. The current study presents a meta-analysis of the effects of prototypic antidepressants in the mouse forced swim test (FST). We identified studies that examined effects of antidepressants in the FST in mice and used standard protocol, male mice and acute drug administration. We calculated Effect sizes using Cohen's d, homogeneity using Q statistic and correlations using Pearson's correlation. Results indicate that all drugs reduce immobility in the FST. However, effect sizes for most drugs are heterogeneous and do not show a consistent dose/response relationship across variability factors. Reducing variability by examining only one strain or data from individual laboratories partially increases dose response relationship. These findings suggest that whereas the FST is a valid tool to qualitatively screen antidepressant effects its validity in the context of hierarchical comparison between doses or compounds might be relevant only to single experiments.
Collapse
Affiliation(s)
- N Z Kara
- School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Israel; Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Israel
| | - Y Stukalin
- School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Israel
| | - H Einat
- School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Israel; Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Israel; College of Pharmacy, University of Minnesota, United States.
| |
Collapse
|
6
|
Sade Y, Toker L, Kara NZ, Einat H, Rapoport S, Moechars D, Berry GT, Bersudsky Y, Agam G. IP3 accumulation and/or inositol depletion: two downstream lithium's effects that may mediate its behavioral and cellular changes. Transl Psychiatry 2016; 6:e968. [PMID: 27922641 PMCID: PMC5315558 DOI: 10.1038/tp.2016.217] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Revised: 08/17/2016] [Accepted: 09/12/2016] [Indexed: 12/12/2022] Open
Abstract
Lithium is the prototype mood stabilizer but its mechanism is still unresolved. Two hypotheses dominate-the consequences of lithium's inhibition of inositol monophosphatase at therapeutically relevant concentrations (the 'inositol depletion' hypothesis), and of glycogen-synthase kinase-3. To further elaborate the inositol depletion hypothesis that did not decisively determine whether inositol depletion per se, or phosphoinositols accumulation induces the beneficial effects, we utilized knockout mice of either of two inositol metabolism-related genes-IMPA1 or SMIT1, both mimic several lithium's behavioral and biochemical effects. We assessed in vivo, under non-agonist-stimulated conditions, 3H-inositol incorporation into brain phosphoinositols and phosphoinositides in wild-type, lithium-treated, IMPA1 and SMIT1 knockout mice. Lithium treatment increased frontal cortex and hippocampal phosphoinositols labeling by several fold, but decreased phosphoinositides labeling in the frontal cortex of the wild-type mice of the IMPA1 colony strain by ~50%. Inositol metabolites were differently affected by IMPA1 and SMIT1 knockout. Inositoltrisphosphate administered intracerebroventricularly affected bipolar-related behaviors and autophagy markers in a lithium-like manner. Namely, IP3 but not IP1 reduced the immobility time of wild-type mice in the forced swim test model of antidepressant action by 30%, an effect that was reversed by an antagonist of all three IP3 receptors; amphetamine-induced hyperlocomotion of wild-type mice (distance traveled) was 35% reduced by IP3 administration; IP3 administration increased hippocampal messenger RNA levels of Beclin-1 (required for autophagy execution) and hippocampal and frontal cortex protein levels ratio of Beclin-1/p62 by about threefold (p62 is degraded by autophagy). To conclude, lithium affects the phosphatidylinositol signaling system in two ways: depleting inositol, consequently decreasing phosphoinositides; elevating inositol monophosphate levels followed by phosphoinositols accumulation. Each or both may mediate lithium-induced behavior.
Collapse
Affiliation(s)
- Y Sade
- Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel,Psychiatry Research Unit, Ben-Gurion University of the Negev, Beer-Sheva, Israel,Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel,Mental Health Center, Beer-Sheva, Israel
| | - L Toker
- Department of Psychiatry and Centre for High-Throughput Biology, University of British Columbia Vancouver, BC, Canada
| | - N Z Kara
- Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel,Psychiatry Research Unit, Ben-Gurion University of the Negev, Beer-Sheva, Israel,Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel,School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel Aviv, Israel
| | - H Einat
- School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel Aviv, Israel
| | - S Rapoport
- Brain Physiology and Metabolism Section, Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | - D Moechars
- Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium
| | - G T Berry
- Metabolism Program Division of Genetics, Children's Hospital Boston, Harvard Medical School, Boston, MA, USA
| | - Y Bersudsky
- Psychiatry Research Unit, Ben-Gurion University of the Negev, Beer-Sheva, Israel,Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel,Mental Health Center, Beer-Sheva, Israel
| | - G Agam
- Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva, Israel,Psychiatry Research Unit, Ben-Gurion University of the Negev, Beer-Sheva, Israel,Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel,Mental Health Center, Beer-Sheva, Israel,Professor, , Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev or Psychiatry Research Unit, Ben-Gurion University of the Negev or Faculty of Health Sciences, Ben-Gurion University of the Negev or Mental Health Center, Beer-Sheva 84170, Israel. E-mail:
| |
Collapse
|
7
|
Kara NZ, Agam G, Anderson GW, Zitron N, Einat H. Lack of effect of chronic ketamine administration on depression-like behavior and frontal cortex autophagy in female and male ICR mice. Behav Brain Res 2016; 317:576-580. [PMID: 27686025 DOI: 10.1016/j.bbr.2016.09.056] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Revised: 09/23/2016] [Accepted: 09/24/2016] [Indexed: 01/05/2023]
Abstract
The acute antidepressant effects of ketamine provide hope for the development of a fast acting approach to treat depression but the consequences of chronic treatment with ketamine are still unclear. One theory regarding the acute effect is that ketamine acts through activation of mTOR but chronic activation of mTOR may lead to reduced autophagy and reduced autophagy could have negative consequences on neuronal plasticity and survival and on affect. To study the interaction between chronic ketamine administration, autophagy and depression the present study tested the effects of 3 weeks daily administration of 5 or 10mg/kg ketamine in both female and male ICR mice on behavior in the open field and the forced swim test and on frontal cortex levels of beclin-1 and p62, two proteins that serve as markers of autophagy. The results show that acute administration of ketamine results in an antidepressant-like effect in the FST, chronic ketamine had no effects in the behavioral tests. There was no difference in the acute or chronic groups between female and male mice. Additionally, chronic ketamine did not alter frontal cortex levels of autophagy markers. The present study suggests that in ICR mice, chronic ketamine does not have the same clear effects that are seen after acute treatment. The lack of difference between females and males and the lack of effects on autophagy after chronic treatment is discussed.
Collapse
Affiliation(s)
- N Z Kara
- School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel-Aviv, Israel; Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beersheba, Israel
| | - G Agam
- Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beersheba, Israel
| | - G W Anderson
- College of Pharmacy, University of Minnesota, Duluth, USA
| | - N Zitron
- School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel-Aviv, Israel
| | - H Einat
- School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel-Aviv, Israel; Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beersheba, Israel; College of Pharmacy, University of Minnesota, Duluth, USA.
| |
Collapse
|
8
|
Kara N, Narayanan S, Belmaker RH, Einat H, Vaidya VA, Agam G. Chronic Lithium Treatment Enhances the Number of Quiescent Neural Progenitors but Not the Number of DCX-Positive Immature Neurons. Int J Neuropsychopharmacol 2015; 18:pyv003. [PMID: 25636892 PMCID: PMC4540105 DOI: 10.1093/ijnp/pyv003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 01/07/2015] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The term adult neurogenesis constitutes a series of developmental steps including the birth, survival, differentiation, maturation, and even death of newborn progenitor cells within neurogenic niches. Within the hippocampus progenitors reside in the neurogenic niche of the subgranular zone in the dentate gyrus subfield. At the different stages, designated type-I, type-IIa, type-IIb, type-III, and granule cell neurons, the cells express a series of markers enabling their identification and visualization. Lithium has been shown to increase hippocampal cell proliferation in the subgranular zone of the hippocampal dentate gyrus subfield of adult rodents and to stimulate the proliferation of hippocampal progenitor cells in vitro, but data regarding lithium's ability to increase neuronal differentiation and survival is equivocal. METHODS To clarify the effect of lithium on adult hippocampal neurogenesis, we identified the effect of chronic lithium treatment on distinct stages of hippocampal progenitor development using adult Nestin-green fluorescent protein transgenic mice and immunofluorescent techniques. RESULTS The present observations confirm that lithium targets the initial stages of progenitor development enhancing the turnover of quiescent neural progenitors/putative stem-cells, corroborating previous reports. However, the enhanced quiescent neural progenitor-turnover does not translate into an increased number of immature neurons. We also observed a steep decline in the number of type-III immature neurons with complex tertiary-dendrites, suggesting that lithium alters the morphological maturation of newborn neurons. CONCLUSIONS Our results do not corroborate previous reports of lithium-induced enhanced numbers of newly generated neurons.
Collapse
Affiliation(s)
- N Kara
- Department of Clinical Biochemistry and Pharmacology (Ms Kara and Dr Agam), and Psychiatry Research Unit (Ms Kara and Drs Belmaker and Agam), Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Mental Health Center, Beer-Sheva, Israel (Ms Kara and Dr Agam); Tel Aviv-Yaffo Academic College, Tel Aviv-Yaffo, Israel (Ms Kara and Dr Einat); Tata Institute of Fundamental Research, Mumbai, India (Ms Narayanan and Dr Vaidya); University of Minnesota, Minneapolis, Minnesota (Dr Einat)
| | - S Narayanan
- Department of Clinical Biochemistry and Pharmacology (Ms Kara and Dr Agam), and Psychiatry Research Unit (Ms Kara and Drs Belmaker and Agam), Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Mental Health Center, Beer-Sheva, Israel (Ms Kara and Dr Agam); Tel Aviv-Yaffo Academic College, Tel Aviv-Yaffo, Israel (Ms Kara and Dr Einat); Tata Institute of Fundamental Research, Mumbai, India (Ms Narayanan and Dr Vaidya); University of Minnesota, Minneapolis, Minnesota (Dr Einat)
| | - R H Belmaker
- Department of Clinical Biochemistry and Pharmacology (Ms Kara and Dr Agam), and Psychiatry Research Unit (Ms Kara and Drs Belmaker and Agam), Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Mental Health Center, Beer-Sheva, Israel (Ms Kara and Dr Agam); Tel Aviv-Yaffo Academic College, Tel Aviv-Yaffo, Israel (Ms Kara and Dr Einat); Tata Institute of Fundamental Research, Mumbai, India (Ms Narayanan and Dr Vaidya); University of Minnesota, Minneapolis, Minnesota (Dr Einat)
| | - H Einat
- Department of Clinical Biochemistry and Pharmacology (Ms Kara and Dr Agam), and Psychiatry Research Unit (Ms Kara and Drs Belmaker and Agam), Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Mental Health Center, Beer-Sheva, Israel (Ms Kara and Dr Agam); Tel Aviv-Yaffo Academic College, Tel Aviv-Yaffo, Israel (Ms Kara and Dr Einat); Tata Institute of Fundamental Research, Mumbai, India (Ms Narayanan and Dr Vaidya); University of Minnesota, Minneapolis, Minnesota (Dr Einat)
| | - V A Vaidya
- Department of Clinical Biochemistry and Pharmacology (Ms Kara and Dr Agam), and Psychiatry Research Unit (Ms Kara and Drs Belmaker and Agam), Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Mental Health Center, Beer-Sheva, Israel (Ms Kara and Dr Agam); Tel Aviv-Yaffo Academic College, Tel Aviv-Yaffo, Israel (Ms Kara and Dr Einat); Tata Institute of Fundamental Research, Mumbai, India (Ms Narayanan and Dr Vaidya); University of Minnesota, Minneapolis, Minnesota (Dr Einat)
| | - G Agam
- Department of Clinical Biochemistry and Pharmacology (Ms Kara and Dr Agam), and Psychiatry Research Unit (Ms Kara and Drs Belmaker and Agam), Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Mental Health Center, Beer-Sheva, Israel (Ms Kara and Dr Agam); Tel Aviv-Yaffo Academic College, Tel Aviv-Yaffo, Israel (Ms Kara and Dr Einat); Tata Institute of Fundamental Research, Mumbai, India (Ms Narayanan and Dr Vaidya); University of Minnesota, Minneapolis, Minnesota (Dr Einat).
| |
Collapse
|
9
|
Toker L, Kara N, Hadas I, Einat H, Bersudsky Y, Belmaker RH, Agam G. Acute intracerebroventricular inositol does not reverse the effect of chronic lithium treatment in the forced swim test. Neuropsychobiology 2014; 68:189-92. [PMID: 24157652 DOI: 10.1159/000355294] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Accepted: 08/26/2013] [Indexed: 11/19/2022]
Abstract
BACKGROUND Lithium has numerous biochemical effects but it is difficult to dissect which of these is responsible for its therapeutic action in bipolar disorder. In the current study we aimed to address one of the major hypotheses, the inositol depletion hypothesis. This hypothesis postulates that lithium's mood-stabilizing effect is mediated by the depletion of brain inositol levels and the subsequent effect on cellular signaling. METHODS We studied whether acute intracerebroventricular (ICV) administration of myo-inositol could reverse the antidepressant-like effect of chronic lithium treatment in the forced swim test (FST). RESULTS In contrast with our prediction, acute myo-inositol administration did not reverse the effect of chronic lithium to decrease immobility in the FST. CONCLUSIONS The results of the present study are limited due to the following: (1) inositol was given acutely while possible events downstream of inositol depletion might require a longer period and (2) ICV inositol may not have reached those areas of the brain involved in the FST.
Collapse
Affiliation(s)
- L Toker
- Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
| | | | | | | | | | | | | |
Collapse
|
10
|
Affiliation(s)
| | | | - H. Einat
- College of Pharmacy, University of Minnesota, Duluth, MN, USA; Department of Psychology, University of Minnesota, Duluth, MN, USA
| |
Collapse
|
11
|
Cleary C, Linde JAS, Hiscock KM, Hadas I, Belmaker RH, Agam G, Flaisher-Grinberg S, Einat H. Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res Bull 2008; 76:469-73. [PMID: 18534253 DOI: 10.1016/j.brainresbull.2008.03.005] [Citation(s) in RCA: 101] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2007] [Revised: 02/28/2008] [Accepted: 03/10/2008] [Indexed: 11/17/2022]
Abstract
Lithium, the prototypic mood stabilizer, was recently demonstrated to enhance autophagy in cells. Recent hypotheses regarding the source of therapeutic effects of lithium as well as other mood stabilizers and antidepressants suggest that they may stem from increased neuroprotection, cellular plasticity and resilience. Hence it is clearly a possibility that enhanced autophagy may be involved in the therapeutic action by contributing to increased cellular resilience. A well-documented mechanism to induce autophagy is by inhibition of mTOR, a negative modulator of autophagy and rapamycin (sirolimus) is a commonly used inhibitor of mTOR. Accordingly, the present study was designed to evaluate the effects of rapamycin in animal models of antidepressant activity. A dose-response experiment in the mice forced swim test was performed and followed by additional testing of mice and rats in an open field, the forced swim test and the tail suspension test. Results show that sub-chronic, but not acute, administration of rapamycin doses of 10mg/kg and above, have an antidepressant-like effect in both mice and rats and in both the forced swim and the tail suspension tests with no effects on the amount or distribution of activity in the open field. Whereas it is tempting to conclude that the antidepressant-like effects are related to mTOR inhibition, they may also be the consequences of interactions with other intracellular pathways. Additional studies are now planned to further explore the behavioral range of rapamycin's effects as well as the biological mechanisms underlying these effects.
Collapse
Affiliation(s)
- C Cleary
- Integrated Biosciences Graduate Program, University of Minnesota, Duluth, MN 55812, USA
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Einat H, Tian F, Belmaker RH, Frost JW. Myo-inositol-1-phosphate (MIP) synthase inhibition: in-vivo study in rats. J Neural Transm (Vienna) 2007; 115:55-8. [PMID: 17828434 DOI: 10.1007/s00702-007-0807-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2007] [Accepted: 08/22/2007] [Indexed: 11/26/2022]
Abstract
Lithium and valproate are the prototypic mood stabilizers and have diverse structures and targets. Both drugs influence inositol metabolism. Lithium inhibits IMPase and valproate inhibits MIP synthase. This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced seizures model. This lack of effects may stem from the low contribution of de-novo synthesis to cellular inositol supply or to the inhibition of the de-novo synthesis by lithium itself.
Collapse
Affiliation(s)
- H Einat
- Department of Pharmacy Practice and Pharmaceutical Education, College of Pharmacy, University of Minnesota, Duluth, MN, USA.
| | | | | | | |
Collapse
|
13
|
Einat H, Manji HK, Gould TD, Du J, Chen G. Possible involvement of the ERK signaling cascade in bipolar disorder: Behavioral leads from the study of mutant mice. ACTA ACUST UNITED AC 2003; 16:453-63. [PMID: 14668941 DOI: 10.1358/dnp.2003.16.7.829357] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Despite the devastating impact that bipolar disorder has on the lives of millions worldwide, little is known for certain about its etiology or pathophysiology. Whereas research has traditionally focused on biogenic amines, it is becoming increasingly more apparent that intracellular pathways are involved in the etiology and treatment of the disease and that a true understanding of the pathophysiology of bipolar disorder must address its neurobiology at different physiological levels, that is, molecular, cellular, systems and behavioral levels. There is now considerable biochemical evidence that the antimanic agents lithium and valproate robustly activate the ERK signaling cascade in therapeutically relevant paradigms. This raises the possibility that this pathway may play a role in the antimanic effects of these agents. The present paper reviews behavioral studies that may shed light on the involvement of the ERK pathway in affective-like behaviors in animals. The available literature suggests that genetic manipulations of the brain-derived neurotrophic factor (BDNF)-ERK kinase pathway produces a variety of changes in affective-like behaviors, with most changes consistent with manic-like behavior. Thus, overall, mice with targeted mutation of the BDNF gene exhibited increased spontaneous locomotion and increased response to acute amphetamine, altered response to chronic cocaine, increased aggression, increase in risk-taking behavior, as demonstrated by time spent in the center of an open field, and changes in eating patterns. Although it has to be acknowledged that the currently available behavioral data from the BDNF-ERK pathway mutants is less than ideal to offer real substantiation relating this pathway to bipolar disorder, the data still supports the possibility that this pathway modulates manic-like behavior in animals, and perhaps mania in humans.
Collapse
Affiliation(s)
- H Einat
- Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-4405, USA.
| | | | | | | | | |
Collapse
|
14
|
Shaldubina A, Einat H, Szechtman H, Shimon H, Belmaker RH. Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm (Vienna) 2002; 109:433-40. [PMID: 11956963 DOI: 10.1007/s007020200035] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A potential model for bipolar disorder, quinpirole-induced biphasic locomotion, was used for a preliminary evaluation of behavioral effects of oral anticonvulsant treatment. Quinpirole, a D2/D3 agonist, induces a biphasic locomotor response starting with inhibition and followed by excitation, resembling the oscillating nature of bipolar disorder. The present study developed a paradigm for oral administration of anticonvulsants that resulted in therapeutic blood levels and tested the effects of treatment on the quinpirole-induced response. Eleven days treatment with valproate (12 g/liter water), phenytoin (6 g/kg food), and carbamazepine (8 g/kg food) resulted in therapeutic blood levels and in a borderline significant reduction in quinpirole-induced hyperactivity without effects on the hypoactive phase. Valproate effects became more significant at the height of the hyperactivity response. Eleven days treatment with topiramate (30 mg/kg) resulted in a significant attenuation of quinpirole-induced hyperactivity, qualitatively similar to the effects of the other anticonvulsants. The results suggest that mood-stabilizing anticonvulsant drugs including topiramate may attenuate quinpirole-induced hyperactivity.
Collapse
Affiliation(s)
- A Shaldubina
- Zlotowski Center for Neuroscience, Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheva, Israel
| | | | | | | | | |
Collapse
|
15
|
Einat H, Belmaker RH. [Animal models of psychiatric diseases: possibilities, limitations, examples and demonstration of use]. Harefuah 2001; 140:458-63, 568. [PMID: 11420839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Animal models of psychopathology serve as a central tool for psychopharmacologists in their attempts to develop new, more efficient medications for psychiatric disorders, and in the efforts to explore the mechanisms of conventional and novel drugs. The development of efficient models for psychiatric diseases is complicated since the mechanisms of the disorders are not clear, major parts of the diagnosis depend on verbal communication with the patient and many of the symptoms are expressed mainly through the subjective experiences of the afflicted individual. Inspite of these difficulties, effective models were developed for most psychiatric diseases. The development of such models is based on their validation in three different dimensions: face validity--behavioral similarities between the model and the disorder; construct validity--similarities between the mechanisms related to the model and a mechanistic theory of the disease; predictive validity--that the model response to the conventional medications that are effective in the disease and will not respond to drugs that are not effective in the disease. The present paper presents three known models of depression; each induced in a different way and therefore represents a group of models: Reserpine-induced hypoactivity--represents the group of pharmacologically induced models. Forced swim test--represents the group of behaviorally induced models. Flinders Sensitive Line--represents the group of genetically induced models. The use of these models in an attempt to examine the range of action of a new potential antidepressant and its mechanisms of action is demonstrated with a recent set of experiments with inositol.
Collapse
Affiliation(s)
- H Einat
- Beer Sheva Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
| | | |
Collapse
|
16
|
Abstract
BACKGROUND Although rates of cigarette smoking have been found to be higher in schizophrenic and depressed patients than in the general population, data regarding rates in bipolar patients are limited. This study further examines the relationship between bipolar disorder and smoking and compares the rate of smoking in bipolar disorder patients with rates in schizophrenic patients and in the general population. METHOD Seventy bipolar patients and 64 schizophrenic patients (diagnosed using DSM-IV criteria) treated at the largest specialized public bipolar and schizophrenia clinics in southern Israel were interviewed regarding their smoking habits. The interview included a questionnaire relating to personal information, past and present smoking, and drug abuse and the Fagerstrom scale for nicotine dependence. Data from these patients were also compared with data from the general Israeli population. RESULTS Data indicate that the rate of smoking does not appear to differ between bipolar (43.0%) and schizophrenic (45.0%) patients, whereas the rate for both patient groups is higher than that for the general Israeli population (27.5%). Smoking intensity was not found to be different between the 2 groups of patients. CONCLUSION Smoking in patients with schizophrenia was suggested to be related to nicotine cholinergic dysfunction, but this suggestion cannot explain the equally high rates of smoking in bipolar patients. Schizophrenia, bipolar disorder, and smoking may all be related to dopamine transmission, and, therefore, dopaminergic interactions may provide a better explanation for the results.
Collapse
Affiliation(s)
- O Itkin
- Beer Sheva Mental Health Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel
| | | | | |
Collapse
|
17
|
Einat H, Szechtman H. Environmental modulation of both locomotor response and locomotor sensitization to the dopamine agonist quinpirole. Behav Pharmacol 2001; 4:399-403. [PMID: 11224208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
The study tested whether differences in locomotor activation during chronic treatment result in differential behavioral sensitization induced by the D2/D3 dopamine agonist quinpirole. One group of rats received repeated injections of quinpirole in their home cage and another group received this treatment in an alternate environment of similar size. In the home cage, quinpirole induced less locomotion than in the non-home environment. When tested in activity monitors at the end of chronic treatment, the home cage group showed less sensitized locomotion to quinpirole than the non-home cage rats. Thus, the extent of locomotor sensitization to quinpirole appears to be related to the amount of locomotion characteristic of the training environment. Such differential sensitization may reflect a modulation of the hierarchy of expression of quinpirole-enhanced hyperactivity via a non-associative process.
Collapse
Affiliation(s)
- H. Einat
- Department of Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada L8N 3Z5
| | | |
Collapse
|
18
|
Abstract
OBJECTIVES Transcranial magnetic stimulation (TMS) of the brain has been reported to have therapeutic effects in mania, as well as depression. TMS has previously been reported to have effects similar to those of electroconvulsive shock in rat models of depression. METHODS We, therefore, studied TMS in amphetamine-induced hyperactivity as a rat model of mania. RESULTS While two and seven daily TMS sessions significantly reduced activity after amphetamine, twice-daily TMS for 7 days enhanced activity after amphetamine. CONCLUSIONS The results suggest that TMS treatment to rats interacts with the effects of amphetamine; the specific effects may be dependent on the schedule of treatment.
Collapse
Affiliation(s)
- A Shaldivin
- Stanley Center for Bipolar Research, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheba, Israel
| | | | | | | | | |
Collapse
|
19
|
Abstract
The effect of inositol as an antidepressant was previously demonstrated in both animal models of depression-like behavior and in clinical trials. Unlike most antidepressant drugs, inositol does not have a clear target in the synapse and was not demonstrated to alter monoamine levels in the brain. The present study attempted to draw a psychopharmacological profile of inositol's behavioral effects by exploring the interactions between the drug and specific receptor agonists and antagonists in the forced swim test. Rats received inositol treatment (or control) in combination with the serotonergic metabolism inhibitor PCPA or with the noradrenergic neurotoxin DSP-4. Results indicated that PCPA but not DSP-4 abolished the ability of inositol to cause a reduction in immobility time in the forced swim test. In mice, the specific 5-HT(2A)/5-HT(2C) antagonist ritanserin, but not the 5-HT(1A)/5-HT(1B)/beta adrenergic antagonist pindolol, abolished inositol's effect in the forced swim test. The 5-HT(2A)/5-HT(2C) agonist DOI and the 5-HT(1A) agonist 8-OH-DPAT did not have any significant effects on inositol's activity. The present data indicates that the antidepressant effect of inositol may involve 5-HT(2) receptors. It is thus possible that the effects of reuptake antidepressant drugs and the effects of inositol may have a common final pathway.
Collapse
Affiliation(s)
- H Einat
- Beer Sheva Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, P.O. Box 4600, Beer Sheva, Israel.
| | | | | | | | | |
Collapse
|
20
|
Abstract
Clinical trials indicate that inositol may be effective in the treatment of patients with depression, panic disorder and obsessive compulsive disorder (OCD), but not in the treatment of patients with schizophrenia, Alzheimer's disease, ADHD or autism. This spectrum of clinical action parallels that of serotonin selective reuptake inhibitors (SSRIs), but inositol is a precursor in the phosphatidylinositol cycle, a second messenger system distal to the receptor for 5HT-2. To study its mechanism of therapeutic action there is a need to test inositol's activity in animal models of psychopathology. In rats, chronic inositol was demonstrated to increase activity levels, reduce immobility time in the forced swim test and in the reserpine-induced hypoactivity models of depression, and reduce anxiety-like behaviors in the elevated plus-maze. The reduction in anxiety-like behaviors appears to be related to baseline levels of activity. Inositol treatment was not observed to have any effect on amphetamine-induced hyperactivity, apomorphine-induced stereotypy, or on the performance of memory tasks by monkeys. Clinical controlled trials of inositol in patients with depression, panic disorder, and OCD were small, and positive psychoactive effects in animals clearly strengthen the case for further clinical trials and potential for general therapeutic use in humans.
Collapse
Affiliation(s)
- H Einat
- Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheva, Israel
| | | |
Collapse
|
21
|
Kofman O, Einat H, Cohen H, Tenne H, Shoshana C. The anxiolytic effect of chronic inositol depends on the baseline level of anxiety. J Neural Transm (Vienna) 2000; 107:241-53. [PMID: 10847563 DOI: 10.1007/s007020050020] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Inositol, a precursor for membrane phosphoinositides involved in signal transduction, has been found to be clinically effective in a number of psychiatric disorders and to reverse behavioural effects of lithium. To gain insight into the mechanism of action of inositol, it is critical to establish its efficacy in animal models. Following the initial report by Cohen et al. (1997b) that inositol was anxiolytic in the elevated plus maze model of anxiety, the effect of chronic intraperitoneal and chronic dietary inositol administration in rats was tested in four experiments. There was a significant increase in closed arm and total arm entries following chronic injection of inositol, but no effect of inositol when it was given chronically in rat chow. Because the first 2 experiments suggested that the mode of drug administration affected the control levels of anxiety (open arm entries and time in open arms) in control groups, the effect of chronic dietary inositol was tested in rats that were exposed to a mild and a more severe form of stress. Chronic saline injections elevated anxiety in the plus maze, which was only marginally affected by chronic dietary inositol. Following 3 weeks administration of 5% dietary inositol rats were pre-exposed to a cat. There was a clear increase in number of entries into open arms, suggesting an anxiolytic effect of inositol.
Collapse
Affiliation(s)
- O Kofman
- Department of Behavioral Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | | | | | | | | |
Collapse
|
22
|
Wolfson M, Einat H, Bersudsky Y, Berkin V, Belmaker RH, Hertz L. Nordidemnin potently inhibits inositol uptake in cultured astrocytes and dose-dependently augments lithium's proconvulsant effect in vivo. J Neurosci Res 2000; 60:116-21. [PMID: 10723074 DOI: 10.1002/(sici)1097-4547(20000401)60:1<116::aid-jnr12>3.0.co;2-u] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
It has been suggested that inositol uptake across the cell membrane is of importance for maintenance of the inositol pool involved in lithium's therapeutic effect in bipolar disease and in the lithium-pilocarpine seizure test in freely moving rats (measuring the latency of a normally subconvulsive concentration of pilocarpine to seizure induction in the additional presence of lithium). We have tested this hypothesis by: 1) demonstrating an extremely high potency of nordidemnin as an inhibitor of myo-inositol uptake in primary cultures of mouse astrocytes; and 2) determining the dose-response correlation of a nordidemnin-induced decrease in the latency before appearance of seizures in the lithium-pilocarpine test after intracerebroventricular injection of minute samples (10 microl) of virtually isotonic saline solution.
Collapse
Affiliation(s)
- M Wolfson
- Department of Microbiology and Immunology and Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
| | | | | | | | | | | |
Collapse
|
23
|
Abstract
Inositol was reported to have effects in depression, panic disorder and OCD, and in animal models of depression and anxiety. The present study tested whether inositol treatment alters monoamine systems. Brain areas of rats pre-treated with acute or chronic inositol were analysed by HPLC for monoamines and their metabolites and compared to control animals. Inositol treatment had no significant effect on levels of monoamines, their metabolites, or turnover rates compared to controls.
Collapse
Affiliation(s)
- H Einat
- Beer Sheva Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Israel
| | | | | | | | | | | |
Collapse
|
24
|
Abstract
Inositol is a simple polyol precursor in a second messenger system important in brain myo-insitol, the natural isomer, which has been found to be therapeutically effective in depression, panic disorder, and obsessive-compulsive disorder in double-blind controlled trials. Recently, epi-inositol, an unnatural stereoisomer of myo-inositol, was found to have effects similar to those of myo-inositol to reverse lithium-pilocarpine seizures. We measured the behavior of rats in an elevated plus maze model of anxiety after chronic treatment of 11 daily intraperitoneal injections of epi-inositol, myo-inositol, or control solution. Epi-inositol reduced anxiety levels of rats compared with controls, and its effect was stronger than that of myo- inositol. Lithium has been hypothesized to alleviate mania by reducing brain inositol levels. Inositol in brain derives from the second messenger cycle, from new synthesis, or from diet via transport across the blood brain barrier. Because the first two are inhibited by lithium, we propose that an inositol-free diet will augment lithium action in mania by enhancing restriction of inositol.
Collapse
Affiliation(s)
- Y Bersudsky
- Beer-Sheba Mental Health Center, PO Box 4600, Beer-Sheba, Israel
| | | | | | | |
Collapse
|
25
|
Abstract
RATIONALE Myo-inositol is an isomer of glucose that is a precursor in the phosphatidylinositol (PIP) cycle, a source of two second messengers: diacylglycerol (DAG) and inositol triphosphate (IP3). Clinical studies have reported that inositol is effective in relieving symptoms of depression. OBJECTIVE The present study examined the effects of inositol on two animal models of depression: the Porsolt forced swim test, a behaviorally based model; and the reserpine-induced immobility model, a pharmacologically based model. METHODS AND RESULTS Chronic inositol injections (daily for 14 days) of 1.2 g/kg (but not at lower doses) reduced immobility time and increased struggle time in the Porsolt test compared with control animals. The same dose and treatment schedule also reduced complete immobility time but did not affect ambulatory activity in the reserpine test compared with controls. Chronic oral treatment with inositol (10% in food for 14 days) had effects similar to IP inositol in the Porsolt test. CONCLUSIONS The effect of inositol in animal models of depression supports its possible importance as a new treatment for the disorder, and permits research on its mechanisms of action.
Collapse
Affiliation(s)
- H Einat
- Beer Sheva Mental Health Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel
| | | | | | | | | |
Collapse
|
26
|
Einat H, Levine J, Grauer E, MacDonald K, Belmaker RH. Effect of inositol treatment on the behavior of rhesus monkeys: preliminary results. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22:999-1005. [PMID: 9789883 DOI: 10.1016/s0278-5846(98)00054-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
1. The effects of inositol (20 g/day, oral) on spatial learning and spontaneous home-cage behavior of four Rhesus monkeys, were studied in a crossover design. 2. Results indicate no marked inositol effect on learning, memory, or behavior. There was a suggestion of an effect of chronic inositol in reducing cage-induced repetitive behavior as indicated by increased switching between modes of behavior, and reduction in length of longest behavioral about. Furthermore inositol may increase time spent in environmentally- rather than self-oriented behavior. 3. Previous behavioral studies of inositol were performed in rats, which maintain low brain inositol levels compared to primates, including humans. The present study demonstrates the feasibility of primate behavioral studies with inositol, and shows the need for longer time experiments and increased variety of behavioral tests.
Collapse
Affiliation(s)
- H Einat
- Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheva, Israel
| | | | | | | | | |
Collapse
|
27
|
Abstract
Lithium inhibits the enzyme inositol monophosphatase and thus obstructs the enzymatic degradation of inositol triphosphate (IP3) to inositol in the phosphate-phosphoinositide (PIP) cycle. This inhibition may result in reduced availability of the second messengers IP3 and DAG that are derivates of the PIP cycle, and this action is currently a leading hypothesis regarding lithium's therapeutic and prophylactic effect in affective disorders. Inositol is also available to the cell by uptake from the intercellular matrix, and therefore it is possible that compounds that block the uptake may have lithium-like effects. To test this hypothesis, the present study evaluates the effects of two inositol uptake inhibitors, the carbohydrate L-fucose and the cyclodepsipeptide nordidemnin, in a behavioral model of pilocarpine-induced seizures known to be enhanced by lithium. We tested the possibility that L-fucose produces lithium-like effects, or that L-fucose or nordidemnin augment lithium's behavioral effects. Results indicate that acute ICV treatment with L-fucose did not by itself have a lithium-like effect in the behavioral model, but significantly augmented lithium's effect when combined with lithium treatment. Nordidemnin treatment showed similar effects. The results suggest that when inositol monophosphatase is inhibited by lithium, further restriction of cellular inositol availability may result in an augmentation of lithium's behavioral effects. It is possible that such manipulations may be applicable in the treatment of patients with affective disorders, especially patients who are poor responders to lithium monotherapy.
Collapse
Affiliation(s)
- H Einat
- Ministry of Health Mental Health Center, Faculty of Health Sciences, Beer Sheva, Israel
| | | | | | | | | |
Collapse
|
28
|
Abstract
The present study examined post mortem changes in central dopaminergic terminal regions following acute or chronic treatment regimens with the dopamine D2/D3 receptor agonist quinpirole, a psychomotor stimulant which induces pronounced behavioural sensitization when given chronically. Drug-induced changes in nucleus accumbens, striatum and amygdala were bilateral in nature, while in prefrontal cortex (medial prefrontal and anterior cingulate combined), left and right brain regions responded differentially to quinpirole. Acute drug treatment increased dopamine tissue levels in nucleus accumbens and right prefrontal cortex, while the dopamine metabolite 3,4-dihydroxyphenylacetic acid, was decreased in amygdala. In contrast, sensitization to quinpirole was associated with decreased dopamine levels in left prefrontal cortex, and increases in 3,4-dihydroxyphenylacetic acid levels in subcortical structures, particularly striatum and amygdala. Additionally, the increase in striatal 3,4-dihydroxyphenylacetic acid in chronic quinpirole animals was independent of drug treatment on the final day of injections. In summary, quinpirole induces a variety of simultaneous, regional changes in dopaminergic function, with the sensitized condition being primarily associated with an up-regulation of subcortical dopamine activity. While the nucleus accumbens and striatum play a well known role in motor activation and sensitized behaviour, it is concluded that the amygdala and prefrontal cortex have significant modulatory influences on these processes, with the role of the prefrontal cortex being asymmetrical in nature. Given the suggested relevance of behavioural sensitization to psychopathological states in humans, parallels are drawn between the present data and clinical findings, particularly in relation to obsessive-compulsive disorder.
Collapse
Affiliation(s)
- R M Sullivan
- Douglas Hospital Research Center, Department of Psychiatry, McGill University, Montréal, Québec, Canada
| | | | | | | |
Collapse
|
29
|
Golani I, Einat H, Tchernichovski O, Teitelbaum P. Keeping the Body Straight in the Unconstrained Locomotion of Normal and Dopamine-Stimulant-Treated Rats. J Mot Behav 1997; 29:99-112. [PMID: 12453787 DOI: 10.1080/00222899709600825] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
During unconstrained locomotor behavior, rats move in and out of a straight posture of the body (including the head). In the present study, the stability of maintaining a straight body was examined in untreated rats and in rats treated with saline (SAL) or with 1 of 3 dopamine stimulants (n = 4 rats per group). The stability of maintaining a straight body can range from very high (with 0.5 mg/kg quinpirole [QUIN]), to high (first half-session with 5 mg/kg (+)-amphetamine [AMPH]), to very low (second half-session with 5 mg/kg AMPH), or can be maintained at a level similar to that observed in untreated rats (with 1.25mg/kg apomorphine [APO]). Stability was assessed by videotaping the rats and, then, by using frame-by-frame analysis, scoring the cumulative proportion of time spent in a straight posture, the frequency of transitions from one hemisphere to the other without being trapped in the midline plane, and the degree of lateral bending during turning and during walking on a curved path. The present study is one in a series identifying key variables that constrain as many degrees of freedom as possible in rat locomotor behavior. The uncovering of such variables is an indispensible step that precedes dynamic systems stability analysis and provides candidates for key variables for the modeling of motor coordination.
Collapse
Affiliation(s)
- I Golani
- a Department of Zoology George S. Wise Faculty of Life Sciences , Tel Aviv University
| | - H Einat
- a Department of Zoology George S. Wise Faculty of Life Sciences , Tel Aviv University
| | - O Tchernichovski
- a Department of Zoology George S. Wise Faculty of Life Sciences , Tel Aviv University
| | - P Teitelbaum
- b Department of Psychology , University of Florida , Gainesville
| |
Collapse
|
30
|
Einat H, Einat D, Allan M, Talangbayan H, Tsafnat T, Szechtman H. Associational and nonassociational mechanisms in locomotor sensitization to the dopamine agonist quinpirole. Psychopharmacology (Berl) 1996; 127:95-101. [PMID: 8888373 DOI: 10.1007/bf02805980] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A pairing paradigm was employed to explore the contribution of associational mechanisms to the expression of sensitization to the dopamine agonist quinpirole. Rats received ten quinpirole injections in the test environment (Group Paired) or in the home cage (Group Unpaired), and saline in the alternate environment. A third group received saline injections in both environments (Group Acute). Subjects received quinpirole on the 11th injection as a test for locomotor sensitization, and saline on the next injection as a test for conditioned activity. The range of discriminative stimuli predicting a drug versus a non-drug injection was increased across three independent experiments in an effort to detect a possible associational effect. Regardless of the strength of discriminative stimuli, both Paired and Unpaired groups showed locomotor sensitization to 0.5 mg/kg quinpirole compared with the Acute group. However, the Paired group showed more locomotion than the Unpaired group in the last minutes of the sensitization test. With a lower sensitizing dose of quinpirole (0.1 mg/kg) used in one experiment, only the Paired group showed locomotor sensitization. For both doses, the Paired, but not the Unpaired groups showed conditioned locomotion. It is suggested that with moderate doses of quinpirole, expression of locomotor sensitization does not require drug-signalling cues though such signals may have a modulatory influence. With lower quinpirole doses, however, quinpirole sensitization is context-dependent.
Collapse
Affiliation(s)
- H Einat
- Department of Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
31
|
Abstract
Behavioral sensitization induced by intermittent injections of the dopamine agonist quinpirole is characterized by hyperlocomotion and perseveration. This study tested whether in sensitized rats, the expression of perserverative behavior can be independent of hyperlocomotion. Rats received 10 injections of either quinpirole (0.5 mg/kg) or saline in a T-maze apparatus, a procedure that induced locomotor sensitization in the drugged animals. When tested later (under quinpirole) for spontaneous alternation in the same T-maze, in a discrete trial procedure, sensitized rats showed decreased spontaneous alternation, compared either to saline controls or acute quinpirole. The decrease in spontaneous alternation showed a tendency to be lower than chance level of alternation, suggesting perseveration. The possibility is discussed that the sensitization-reduced spontaneous alternation may relate to a diminution in the sense of task completion, and the increased perseveration may model a form of compulsive "checking" shown in obsessive-compulsive disorder.
Collapse
Affiliation(s)
- H Einat
- Department of Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
| | | |
Collapse
|
32
|
Abstract
To assess whether the interval between injections affects the course of locomotor sensitization to quinpirole, groups of rats were injected every 2, 4, or 8 days with quinpirole (0, 0.025, 0.25, 0.5, and 2.5 mg/kg; n = 222) and their locomotor activity monitored after each injection for a total of 10 tests. Results indicate that the number of drug injections, rather than the interval between them, predominantly controls the development of locomotor sensitization to quinpirole. It is suggested that this may reflect a rapid induction but slow decay time for a response-enhancing factor stimulated by each injection of quinpirole, and that the effects of this putative factor are cumulative but saturable.
Collapse
Affiliation(s)
- H Szechtman
- Department of Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada
| | | | | | | | | |
Collapse
|
33
|
Abstract
This study asks whether apart from behavioral sensitization, chronic treatment with the D2 dopamine agonist quinpirole produces long-term effects on undrugged behavior. Rats (n = 12) were pretreated with 10 injections of quinpirole (0.5 mg/kg every 4 days in activity cages), producing a 6-fold increase in locomotor activity. Ten days later, their undrugged behavior was assessed in a large open field, and their spatial learning in a Morris water maze; the entire procedure was repeated 3 months later. Control animals were pretreated with saline and tested in the open field either undrugged (n = 12) or with acute quinpirole (n = 12); only undrugged controls were used for spatial learning. Results indicate that quinpirole pretreatment results in persisting changes that can be characterized as a reduction in the rat's freedom of movement. Compared to vehicle controls, quinpirole pretreated rats turn with a more rigid body, show more repetitive travel along the same routes in the open field, and perseverate more during extinction in the water maze. These effects are weaker at 3 months postsensitization. In all other respects (level of activity in the open field and acquisition learning) Sensitized rats behave no differently from vehicle controls. Changes in undrugged behavior in the open field resemble the effects of quinpirole but are smaller in magnitude. It is suggested that the alteration in undrugged behavior reflects compensatory behavioral adaptation to the exaggerated hyperactivity induced by quinpirole.
Collapse
Affiliation(s)
- H Einat
- Department of Biomedical Sciences, McMaster University, Hamilton, Ont., Canada
| | | |
Collapse
|